News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Newron Pharmaceuticals (NWRN) PD Drug Succeeds in Phase III, $26 Million Zambon Pact Sealed



5/16/2012 7:49:13 AM

Newron Pharmaceuticals S.p.A. (“Newron”), a research and development company focused on novel CNS and pain therapies announces that it has executed with Zambon, the Italian chemical and pharmaceutical Company (“Zambon”), a strategic collaboration and licence agreement for Newron’s lead compound safinamide. In aggregate, the total Zambon investment in Newron will be €20m as defined below, also covering the completion of safinamide’s clinical development and the preparation of the application for marketing approval in Europe and the US.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES